pSivida Corp. (PSDV)

2.22
0.06 2.42
NASDAQ : Health Technology
Prev Close 2.27
Open 2.26
Day Low/High 2.13 / 2.27
52 Wk Low/High 0.93 / 2.88
Volume 300.85K
Avg Volume 358.80K
Exchange NASDAQ
Shares Outstanding 45.16M
Market Cap 51.94M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
PSivida CEO To Present At 17Th Annual BioCEO & Investor Conference February 9

PSivida CEO To Present At 17Th Annual BioCEO & Investor Conference February 9

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr.

PSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2015...

PSivida Reports ILUVIEN® Receives Marketing Authorization In Two More EU Countries

PSivida Reports ILUVIEN® Receives Marketing Authorization In Two More EU Countries

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Finland and Luxembourg have granted marketing authorization to...

PSivida Reports Commencement Of ILUVIEN® Sales In Portugal

PSivida Reports Commencement Of ILUVIEN® Sales In Portugal

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the sale of ILUVIEN® for diabetic macular edema (DME) has...

PSivida Reports ILUVIEN® Granted Marketing Authorization In The Netherlands

PSivida Reports ILUVIEN® Granted Marketing Authorization In The Netherlands

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has...

PSivida CEO To Present At LD Micro Investor Conference

PSivida CEO To Present At LD Micro Investor Conference

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr.

Psivida (PSDV) Upgraded From Sell to Hold

Psivida (PSDV) Upgraded From Sell to Hold

Psivida (PSDV) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRRC, DAC, DVN, JASO, PBF, PSDV, SPLS, WRLD Downgrades: ESRT, MARPS, MTRX, TSLA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

PSivida Reports ILUVIEN® Granted Marketing Authorization In Ireland

PSivida Reports ILUVIEN® Granted Marketing Authorization In Ireland

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Irish Health Products Regulatory Authority (HPRA) has...

PSivida Reports ILUVIEN® Granted Marketing Authorization In Belgium

PSivida Reports ILUVIEN® Granted Marketing Authorization In Belgium

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Belgian Federal Agency for Medicines and Health ...

PSivida Corp. Reports First Quarter FY 2015 Results

PSivida Corp. Reports First Quarter FY 2015 Results

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30,...

PSivida Corp. Announces First Quarter Fiscal 2015 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces First Quarter Fiscal 2015 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the first quarter of fiscal year...

PSivida Corp. Receives $25 Million Milestone Payment

PSivida Corp. Receives $25 Million Milestone Payment

pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that it has received the $25 million milestone payment under its...

Why pSivida (PSDV) Stock Is Soaring in After-Hours Trading Today

Why pSivida (PSDV) Stock Is Soaring in After-Hours Trading Today

Shares of pSivida (PSDV) surged in after-hours trading Friday after the FDA approved the company's eye implant Iluvien after three rejections.

PSivida Corp. Reports FDA Approval Of ILUVIEN® For Diabetic Macular Edema

PSivida Corp. Reports FDA Approval Of ILUVIEN® For Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.

Oversold Conditions For pSivida (PSDV)

Oversold Conditions For pSivida (PSDV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

PSivida Corp. Names James Barry To Board Of Directors

PSivida Corp. Names James Barry To Board Of Directors

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected James J.

PSivida Corp. Reports Fourth Quarter And FY 2014 Results

PSivida Corp. Reports Fourth Quarter And FY 2014 Results

pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its fourth quarter and fiscal year ended...

PSivida Corp Announces Fourth Quarter And Fiscal Year 2014 Financial Results Release Date And Conference Call Information

PSivida Corp Announces Fourth Quarter And Fiscal Year 2014 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the fourth quarter and fiscal...

PSivida Corp. Reports ILUVIEN® For Chronic Diabetic Macular Edema Receives Marketing Authorization In Sweden, 10th EU Approval

PSivida Corp. Reports ILUVIEN® For Chronic Diabetic Macular Edema Receives Marketing Authorization In Sweden, 10th EU Approval

pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Swedish Medical Products Agency granted marketing...

PSivida Corp. Reports ILUVIEN® For Chronic Diabetic Macular Edema Receives Marketing Authorization In Denmark, 9th EU Approval

PSivida Corp. Reports ILUVIEN® For Chronic Diabetic Macular Edema Receives Marketing Authorization In Denmark, 9th EU Approval

pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Danish Health and Medicines Authority granted ...

PSivida Announces ILUVIEN® Receives Marketing Authorization In Norway And Approval For Reimbursement In Portugal

PSivida Announces ILUVIEN® Receives Marketing Authorization In Norway And Approval For Reimbursement In Portugal

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that ILUVIEN® has been has granted marketing ...

PSivida Corp. Reports Positive Regulatory Outcome For ILUVIEN®; Moves To National Phase For Marketing Authorizations In 10 More EU Countries

PSivida Corp. Reports Positive Regulatory Outcome For ILUVIEN®; Moves To National Phase For Marketing Authorizations In 10 More EU Countries

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the regulatory process for marketing authorizations in...

PSivida Announces ILUVIEN® Receives Marketing Authorization In Italy For Treatment Of Chronic Diabetic Macular Edema

PSivida Announces ILUVIEN® Receives Marketing Authorization In Italy For Treatment Of Chronic Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del ...

PSivida Corp. Reports Third Quarter 2014 Results

PSivida Corp. Reports Third Quarter 2014 Results

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its third quarter ended March 31, 2014.

PSivida Presents Preclinical Data Demonstrating Sustained Release Of Avastin Using Tethadur At ARVO Annual Meeting

PSivida Presents Preclinical Data Demonstrating Sustained Release Of Avastin Using Tethadur At ARVO Annual Meeting

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data ...

PSivida Corp Announces Third Quarter 2014 Financial Results Release Date And Conference Call Information

PSivida Corp Announces Third Quarter 2014 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year...

PSivida Reports Australia/New Zealand Distribution Agreement For ILUVIEN® For DME

PSivida Reports Australia/New Zealand Distribution Agreement For ILUVIEN® For DME

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive...

PSivida Selected To Present At 2014 Opthalmology Innovation Summit

PSivida Selected To Present At 2014 Opthalmology Innovation Summit

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The...

PSivida Announces September 26, 2014 PDUFA Date For ILUVIEN®

PSivida Announces September 26, 2014 PDUFA Date For ILUVIEN®

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.